IL7R and type 1 diabetes mellitus: scRNA-seq also helped to reveal biomarkers that could serve as indicators of successful T1DM treatment with teplizumab (IL7R, CD127), and potential targets for monoclonal antibody treatment (TLR4, TRAJ23, IL23).